{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T14:43:14Z","timestamp":1775486594014,"version":"3.50.1"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T00:00:00Z","timestamp":1713830400000},"content-version":"vor","delay-in-days":113,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research & Development, LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>In the absence of axial psoriatic arthritis (axPsA)-specific tools, the BASDAI and Ankylosing Spondylitis Disease Activity Score (ASDAS) are used to assess axial symptoms in patients with PsA. Here, we assessed the performance of BASDAI and ASDAS in patients with PsA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients with active PsA in DISCOVER-1 and DISCOVER-2 (ClinicalTrials.gov: NCT03162796 and NCT03158285, respectively) with or without axPsA but with available baseline BASDAI information were analysed; those with investigator-identified axial symptoms and imaging-confirmed sacroiliitis comprised the axPsA cohort. Correlations between BASDAI\/ASDAS and clinical variables were assessed with Pearson\u2019s coefficient (r). Longitudinal effects of enthesitis (Leeds Enthesitis Index [LEI]), swollen joint count and presence versus absence of axPsA on BASDAI\/ASDAS (normalized 0\u201310 scale) were analysed with mixed models for repeated measures.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>At baseline in the axPsA (n\u2009=\u2009312) and non-axPsA (n\u2009=\u2009124) cohorts, BASDAI scores showed no or weak correlation with swollen joint count (0.18\u20130.20), tender joint count (0.12\u20130.29), LEI (\u20130.04 to 0.24) and physician global assessment (0.35\u20130.43); moderate correlation with fatigue (both \u22120.56); and strong correlation with patient global assessment of disease activity (0.62\u20130.69) and patient-reported pain (0.66\u20130.70). Similar correlations were observed for ASDAS. Axial involvement versus non-involvement was associated with higher BASDAI scores and ASDAS (all \u03b2\u2009\u2265\u20090.5), without differences between instruments; longitudinal associations between swollen joint count (\u03b2\u2009\u2264\u20090.06)\/LEI (\u03b2\u2009\u2264\u20090.19) and BASDAI\/ASDAS were clinically unimportant.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>BASDAI and ASDAS performed similarly in patients with active PsA and axial involvement, independent of peripheral disease involvement, supporting their performance in assessing axial disease activity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration<\/jats:title>\n                  <jats:p>ClinicalTrials.gov, http:\/\/clinicaltrials.gov, NCT03162796 and NCT03158285.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rap\/rkae058","type":"journal-article","created":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T01:56:56Z","timestamp":1713751016000},"source":"Crossref","is-referenced-by-count":7,"title":["BASDAI versus ASDAS in evaluating axial involvement in patients with psoriatic arthritis: a pooled analysis of two phase 3 studies"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9475-9362","authenticated-orcid":false,"given":"Xenofon","family":"Baraliakos","sequence":"first","affiliation":[{"name":"Rheumazentrum Ruhrgebiet, Ruhr-University Bochum , Herne, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9074-0592","authenticated-orcid":false,"given":"Dafna D","family":"Gladman","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Toronto, Schroeder Arthritis Institute; Krembil, Research Institute; Toronto Western Hospital , Toronto, ON, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7957-838X","authenticated-orcid":false,"given":"Soumya D","family":"Chakravarty","sequence":"additional","affiliation":[{"name":"Immunology, Janssen Scientific Affairs, LLC, a Johnson & Johnson company , Horsham, PA, USA"},{"name":"Division of Rheumatology, Drexel University College of Medicine , Philadelphia, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1158-0699","authenticated-orcid":false,"given":"Cinty","family":"Gong","sequence":"additional","affiliation":[{"name":"Immunology, Janssen Research & Development, LLC, a Johnson & Johnson company , Spring House, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6005-3938","authenticated-orcid":false,"given":"May","family":"Shawi","sequence":"additional","affiliation":[{"name":"Immunology, Janssen Research & Development, LLC, a Johnson & Johnson company , Titusville, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanouil","family":"Rampakakis","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, McGill University , Montreal, Canada"},{"name":"Scientific Affairs, JSS Medical Research, Inc , Montreal, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4007-1589","authenticated-orcid":false,"given":"Mitsumasa","family":"Kishimoto","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Rheumatology, Kyorin University School of Medicine , Mitaka, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3143-1084","authenticated-orcid":false,"given":"Enrique R","family":"Soriano","sequence":"additional","affiliation":[{"name":"Rheumatology Section, Internal Medicine Service, Department of Medicine, Hospital Italiano de Buenos Aires , Buenos Aires, Argentina"},{"name":"Department of Medicine, University Institute Hospital Italiano de Buenos Aires , Buenos Aires, Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-0457","authenticated-orcid":false,"given":"Philip J","family":"Mease","sequence":"additional","affiliation":[{"name":"Rheumatology Research, Providence Swedish Medical Center , Seattle, WA, USA"},{"name":"University of Washington School of Medicine , Seattle, WA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,4,23]]},"reference":[{"key":"2024051708241031900_rkae058-B1","doi-asserted-by":"crossref","first-page":"i37","DOI":"10.1093\/rheumatology\/kez383","article-title":"Treatment guidelines in psoriatic arthritis","volume":"59","author":"Ogdie","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2024051708241031900_rkae058-B2","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jaad.2020.05.089","article-title":"Axial psoriatic arthritis: an update for dermatologists","volume":"84","author":"Gottlieb","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2024051708241031900_rkae058-B3","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.semarthrit.2021.06.006","article-title":"Axial involvement in psoriatic arthritis: an update for rheumatologists","volume":"51","author":"Poddubnyy","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"2024051708241031900_rkae058-B4","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1007\/s12325-023-02475-4","article-title":"Genetic and molecular distinctions between axial psoriatic arthritis and radiographic axial spondyloarthritis: post hoc analyses from four phase 3 clinical trials","volume":"40","author":"Kavanaugh","year":"2023","journal-title":"Adv Ther"},{"key":"2024051708241031900_rkae058-B5","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1136\/annrheumdis-2015-209068","article-title":"Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1\/PSUMMIT-2)","volume":"75","author":"Kavanaugh","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2024051708241031900_rkae058-B6","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/art.40728","article-title":"Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2024051708241031900_rkae058-B7","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1136\/annrheumdis-2018-213328","article-title":"Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study","volume":"77","author":"Baeten","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2024051708241031900_rkae058-B8","year":"2020"},{"key":"2024051708241031900_rkae058-B9","doi-asserted-by":"crossref","first-page":"e715","DOI":"10.1016\/S2665-9913(21)00105-3","article-title":"Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies","volume":"3","author":"Mease","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"2024051708241031900_rkae058-B10","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1007\/s40744-023-00592-8","article-title":"Efficacy of guselkumab on axial-related symptoms through up to 2 years in adults with active psoriatic arthritis in the phase 3, randomized, placebo-controlled DISCOVER-2 study","volume":"10","author":"Mease","year":"2023","journal-title":"Rheumatol Ther"},{"key":"2024051708241031900_rkae058-B11","doi-asserted-by":"crossref","first-page":"e187","DOI":"10.1136\/annrheumdis-2022-222161","article-title":"Correspondence on \u2018No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related \u2019physician-reported spondylitis'?' by Braun and Landewe","volume":"82","author":"Gladman","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2024051708241031900_rkae058-B12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1759720X211057975","article-title":"Axial Involvement in Psoriatic Arthritis cohort (AXIS): the protocol of a joint project of the Assessment of SpondyloArthritis international Society (ASAS) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)","volume":"13","author":"Poddubnyy","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2024051708241031900_rkae058-B13","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett","year":"1994","journal-title":"J Rheumatol"},{"key":"2024051708241031900_rkae058-B14","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1136\/ard.2008.094870","article-title":"Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis","volume":"68","author":"Lukas","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2024051708241031900_rkae058-B15","article-title":"Use of the BASDAI in psoriatic arthritis patients with and without axial disease","volume":"72(Suppl 10)","author":"Reddy","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2024051708241031900_rkae058-B16","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3899\/jrheum.210662","article-title":"Evaluation of clinical diagnosis of axial psoriatic arthritis (PsA) or elevated patient-reported spine pain in CorEvitas\u2019 PsA\/spondyloarthritis registry","volume":"49","year":"2022","journal-title":"J Rheumatol"},{"key":"2024051708241031900_rkae058-B17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2017-211734","article-title":"Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force","volume":"77","author":"Smolen","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2024051708241031900_rkae058-B18","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.autrev.2014.01.050","article-title":"The IL-23\/IL-17 axis in psoriatic arthritis","volume":"13","author":"Suzuki","year":"2014","journal-title":"Autoimmun Rev"},{"key":"2024051708241031900_rkae058-B19","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","article-title":"Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF\u03b1 inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet"},{"key":"2024051708241031900_rkae058-B20","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","article-title":"Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Mease","year":"2020","journal-title":"Lancet"},{"key":"2024051708241031900_rkae058-B21","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1136\/ard.2010.129726","article-title":"Is ASDAS better than BASDAI as a measure of disease activity in axial psoriatic arthritis?","volume":"69","author":"Eder","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2024051708241031900_rkae058-B22","author":"European Alliance of Associations for Rheumatology (EULAR)"},{"key":"2024051708241031900_rkae058-B23","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/art.23568","article-title":"Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis","volume":"59","author":"Healy","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2024051708241031900_rkae058-B24","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1477-7525-1-79","article-title":"The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: properties, applications, and interpretation","volume":"1","author":"Webster","year":"2003","journal-title":"Health Qual Life Outcomes"},{"key":"2024051708241031900_rkae058-B25","doi-asserted-by":"crossref","DOI":"10.4135\/9781483381411","volume-title":"The SAGE encyclopedia of communication research methods","author":"Allen","year":"2017"},{"key":"2024051708241031900_rkae058-B26","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s10067-014-2734-8","article-title":"Comparison of ASDAS and BASDAI as a measure of disease activity in axial psoriatic arthritis","volume":"34","author":"K\u0131l\u0131\u00e7","year":"2015","journal-title":"Clin Rheumatol"},{"key":"2024051708241031900_rkae058-B27","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1186\/s13063-022-06589-y","article-title":"Efficacy and safety of guselkumab in biologic-naive patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial","volume":"23","author":"Gladman","year":"2022","journal-title":"Trials"},{"key":"2024051708241031900_rkae058-B28","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1136\/annrheumdis-2020-217232","article-title":"Central reader evaluation of MRI scans of the sacroiliac joints from the ASAS classification cohort: discrepancies with local readers and impact on the performance of the ASAS criteria","volume":"79","author":"Maksymowych","year":"2020","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology Advances in Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumap\/advance-article-pdf\/doi\/10.1093\/rap\/rkae058\/57310779\/rkae058.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumap\/article-pdf\/8\/2\/rkae058\/57722783\/rkae058.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumap\/article-pdf\/8\/2\/rkae058\/57722783\/rkae058.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T08:51:10Z","timestamp":1715935870000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumap\/article\/doi\/10.1093\/rap\/rkae058\/7656778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,1]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3,14]]}},"URL":"https:\/\/doi.org\/10.1093\/rap\/rkae058","relation":{},"ISSN":["2514-1775"],"issn-type":[{"value":"2514-1775","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1,1]]},"published":{"date-parts":[[2024,1,1]]},"article-number":"rkae058"}}